• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review

  • ID: 1290947
  • April 2015
  • Region: Global
  • 61 pages
  • GlobalData

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- READ MORE >

Note: Product cover images may vary from those shown

List of Tables
List of Figures
Section 1 - About the Company
Valeant Pharmaceuticals International, Inc. - Key Facts
Valeant Pharmaceuticals International, Inc. - Key Employees
Valeant Pharmaceuticals International, Inc. - Key Employee Biographies
Valeant Pharmaceuticals International, Inc. - Major Products and Services
Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc. - History
Valeant Pharmaceuticals International, Inc. - Company Statement
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Valeant Pharmaceuticals International, Inc. - Business Description
Valeant Pharmaceuticals International, Inc. - Corporate Strategy
Valeant Pharmaceuticals International, Inc. - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International, Inc. - Strengths
Strength - Diversified Product Portfolio
Strength - Focus on Research & Development
Strength - Diversified Operational Presence
Valeant Pharmaceuticals International, Inc. - Weaknesses
Weakness - Dependence on Major Customers
Valeant Pharmaceuticals International, Inc. - Opportunities
Opportunity - Market Potential - Central Nervous System
Opportunity - Global Dermatology Market
Opportunity - Inorganic Growth: Strategic Acquisitions
Valeant Pharmaceuticals International, Inc. - Threats
Threat - Intense Competition
Threat - Uncertainties in R&D
Threat - Stringent Government Regulations
Valeant Pharmaceuticals International, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 02, 2015: Valeant Pharmaceuticals Lays Off 77 Employees In Seattle
Feb 22, 2015: Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results
Dec 09, 2014: Valeant To Abandon Growth-by-Acquisitions Strategy For Time Being To Cut Debt And Boost Stock
Nov 13, 2014: Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey
Nov 04, 2014: Allergan Comments on California Federal Court Ruling in Insider Trading Lawsuit Against Valeant & Pershing Square
Oct 20, 2014: Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results
Sep 30, 2014: Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA
Sep 25, 2014: Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals
Sep 08, 2014: Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester
Sep 02, 2014: Allergan Files Answer in Federal Court Responding to Valeant and Pershing Square’s Counterclaims
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Valeant Pharmaceuticals International, Inc., Key Facts
Valeant Pharmaceuticals International, Inc., Key Employees
Valeant Pharmaceuticals International, Inc., Key Employee Biographies
Valeant Pharmaceuticals International, Inc., Major Products and Services
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage
Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase
Valeant Pharmaceuticals International, Inc., History
Valeant Pharmaceuticals International, Inc., Other Locations
Valeant Pharmaceuticals International, Inc., Subsidiaries
Valeant Pharmaceuticals International, Inc., Key Competitors
Valeant Pharmaceuticals International, Inc., Ratios based on current share price
Valeant Pharmaceuticals International, Inc., Annual Ratios
Valeant Pharmaceuticals International, Inc., Interim Ratios
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc., Performance Chart (2010 - 2014)
Valeant Pharmaceuticals International, Inc., Ratio Charts
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015

Note: Product cover images may vary from those shown

Kali Laboratories, Inc.
Teva Pharmaceutical Industries Limited
Actavis, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Grifols, S.A. Takeda Pharmaceutical Company Limited Alexion Pharmaceuticals Teva Pharmaceutical Industries Ltd. Endo International Plc. Essilor International S.A.